Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1964 1
1965 1
1969 2
1971 1
1972 1
1978 1
1979 2
1984 1
1988 5
1989 7
1990 7
1991 7
1992 5
1993 1
1994 2
1995 4
1996 3
1997 7
1998 2
1999 1
2000 3
2001 1
2003 2
2004 1
2007 2
2008 2
2009 3
2010 6
2011 6
2012 5
2013 6
2014 11
2015 13
2016 4
2017 16
2018 16
2019 19
2020 21
2021 24
2022 15
2023 14
2024 29
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Cancer misinformation on social media.
Loeb S, Langford AT, Bragg MA, Sherman R, Chan JM. Loeb S, et al. Among authors: langford at. CA Cancer J Clin. 2024 Sep-Oct;74(5):453-464. doi: 10.3322/caac.21857. Epub 2024 Jun 19. CA Cancer J Clin. 2024. PMID: 38896503 Free PMC article. Review.
Guidelines on the management of abnormal liver blood tests.
Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A. Newsome PN, et al. Among authors: langford a. Gut. 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924. Epub 2017 Nov 9. Gut. 2018. PMID: 29122851 Free PMC article.
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Kumar ASR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, McJannett M, Thomas H, Langford A, Hofman MS, Martin AJ, Davis ID, Stockler MR; ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: langford a. Lancet Oncol. 2025 Mar;26(3):291-299. doi: 10.1016/S1470-2045(25)00009-9. Epub 2025 Feb 13. Lancet Oncol. 2025. PMID: 39956124 Clinical Trial.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: langford a. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12. Lancet Oncol. 2024. PMID: 38621400 Clinical Trial.
Endurance.
Langford A. Langford A. Lancet Psychiatry. 2019 Jun;6(6):474. doi: 10.1016/S2215-0366(19)30171-3. Lancet Psychiatry. 2019. PMID: 31122481 No abstract available.
Achieving sustainable healthcare through deprescribing.
Gnjidic D, Johansson M, Meng DM, Farrell B, Langford A, Reeve E. Gnjidic D, et al. Among authors: langford a. Cochrane Database Syst Rev. 2022 Oct 4;10(10):ED000159. doi: 10.1002/14651858.ED000159. Cochrane Database Syst Rev. 2022. PMID: 36194519 Free PMC article. No abstract available.
Epigenetic silencing of a multifunctional plant stress regulator.
Zander M, Willige BC, He Y, Nguyen TA, Langford AE, Nehring R, Howell E, McGrath R, Bartlett A, Castanon R, Nery JR, Chen H, Zhang Z, Jupe F, Stepanova A, Schmitz RJ, Lewsey MG, Chory J, Ecker JR. Zander M, et al. Among authors: langford ae. Elife. 2019 Aug 16;8:e47835. doi: 10.7554/eLife.47835. Elife. 2019. PMID: 31418686 Free PMC article.
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee ST, Scott AM, Martin AJ, Stockler MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW; TheraP Investigators and the ANZUP Cancer Trials Group. Kwan EM, et al. Nat Med. 2025 Aug;31(8):2722-2736. doi: 10.1038/s41591-025-03704-9. Epub 2025 May 27. Nat Med. 2025. PMID: 40425844 Clinical Trial.
271 results